18 results about "IGFBP7" patented technology

The present invention provides a probiotic active antibacterial tablet for preventing and treating female reproductive system infection and a preparation method thereof. The present invention is a probiotic active antibacterial tablet for preventing and treating female reproductive system infection, comprising the following raw materials in parts by weight: 1.8-2.5 parts of Lactobacillus reuteri, 1.0-1.2 parts of Lactobacillus rhamnosus, 1.2-1.7 parts of Lactobacillus crispatus, 0.5-0.8 parts of Lactobacillus gasseri, 1.0-1.5 parts of stachyose, 0.8-1.2 parts of inulin, and 2.5-3 parts of plant extract, wherein the plant extract is prepared from the following raw materials: Bletilla striata, Chinese tallow tree leaf, Gentiana scabra, and grapefruit seed. The probiotic active antibacterial tablet prepared by the present invention has a significant inhibitory effect on IGFBP7 protein, can effectively prevent and treat female reproductive system infection, and has good tolerance and safety.

The invention relates to application of IGFBP7 in clinical diagnosis of colorectal cancer and application of IGFBP7 as a drug target. The research shows that the expression quantity of IGFBP7 secreted by tumor endothelial cells is continuously reduced in the colorectal tumor formation process related to inflammation. Functional analysis proves that the endothelial-derived IGFBP7 is secreted into a tumor microenvironment and plays a role in resisting angiogenesis. In addition, the CRC cells can actively ingest the vesicles containing the IGFBP7. The IGFBP7 reduces the activity of a TGF-beta1 signal channel by inhibiting the expression of EGR1, thereby inhibiting the proliferation and migration of tumor cells. What is worthy of attention is that VAPA (Vesicle-associated Membrane Protein Associated Protein A) is identified to be a key factor for mediating IGFBP7 vesicles to be transferred to lysosome, and VAPA promotes the degradation of IGFBP7, so that the cancer suppression function of the IGFBP7 is weakened. The endothelial cell-derived IGFBP7 inhibits the progress of CRC (cyclic redundancy check) through an EGR1 / TGF-beta 1 pathway, and VAPA-mediated lysosome degradation limits the cancer inhibition effect of the endothelial cell-derived IGFBP7. The discovery emphasizes that the endothelial cell-derived IGFBP7 is a promising therapeutic target in the field of colorectal cancer.

The application belongs to the technical field of biotechnology, and particularly relates to a pharmaceutical composition containing exosomes and application thereof. The pharmaceutical composition containing exosomes comprises stem cell exosomes, recombinant IGFBP7 protein and baeckea fruitin B; the amino acid sequence of the recombinant IGFBP7 protein is shown as SEQ ID NO:1. Test results show that the combination of umbilical cord mesenchymal stem cell exosomes, baeckea fruitin B and recombinant IGFBP7 protein can stimulate hair follicle stem cells, prolong the initial stage of hair growth of hair follicles, and thus effectively improve the hair loss of patients.

The invention discloses an anti-human IGFBP7 monoclonal antibody and application thereof, and relates to the technical field of immunotherapy, in particular to the anti-human IGFBP7 monoclonal antibody aiming at an IGFBP7 target spot, after the anti-human IGFBP7 monoclonal antibody is adopted for treatment, the inflammation of a mouse is obviously relieved, the skin vascular system is recovered, and the anti-human IGFBP7 monoclonal antibody has a treatment effect on endothelial dysfunction and psoriasis.

The invention belongs to the technical field of protein polypeptides, and particularly discloses a CD93 affinity peptide and application thereof in preparation of antitumor drugs or detection reagents. The polypeptide with a CD93 protein affinity effect is obtained through repeated screening and optimization, and an affinity blocking activity experiment proves that the CD93 affinity peptide can affine an extracellular IgV-like structural domain of the CD93 protein and block the interaction of CD93 / IGFBP7 protein. An HUVECs cell in-vitro migration experiment and a tube formation experiment verify that the CD93 affinity peptide can inhibit migration of HUVECs cells and tube formation, promote normalization of tumor vascular functions and further inhibit growth of tumors, and has no obvious toxic or side effect. The CD93 affinity peptide provided by the invention can be used for preparing anti-tumor drugs (including anti-tumor immunotherapy drugs) or detection reagents taking CD93 as a target spot, has a better medical application prospect, and provides a new choice for tumor immunotherapy.

The present invention relates to an antibody or antigen binding fragment thereof that binds specifically to IGFBP7 and has pro-survival activity, decreases stress-mediated senescence / inflammation and pro-fibrotic tissue injury. In particular, the invention relates to antibodies or antigen binding fragments thereof that bind with high affinity and specificity to human IGFBP7 and / or to at least one of its receptors.

The invention relates to the technical field of pharmaceutical biology, aims to solve the problem of lack of specific detoxification drugs for treating glyphosate poisoning clinically, and particularly provides application of chlorogenic acid in preparation of drugs for treating glyphosate-induced renal toxicity diseases. The drug mechanism of the chlorogenic acid is as follows: glyphosate-induced renal toxicity is antagonized through targeted renal injury biomarkers, wherein the renal injury biomarkers comprise TIM-1, TIMP-2, IGFBP7 and LCN2. The invention also provides a preparation for preventing and / or relieving and / or treating glyphosate-induced renal toxicity diseases, wherein the preparation contains chlorogenic acid. The preparation can be a medicine, a pharmaceutical composition, a health care product, a food or an additive. The medicine prepared by the invention can be used for remarkably reducing the expression levels of TIM-1, TIMP-2, IGFBP7 and LCN2 of the GLY-induced renal injury. In addition, oxidative stress (LCN2), cell cycle arrest (TIMP-2 / IGFBP7) and inflammatory reaction (TIM-1) can be synchronously and accurately inhibited, and the curative effect is superior to that of a current single-channel medicine.

To enable rapid and accurate diagnosis of oral lichen planus on the basis of a noninvasive and easily accessible sample such as saliva.SOLUTION: The present invention relates to a biomarker composition for diagnosing oral lichen planus, which is selected from the group consisting of CLC, TNFAIP8, EVI5L, ISG15, PIGS, SLC4A1, MYH1, CLTA, CCAR2, GRK6, ATP5F1D, ASRGL1, BST1, CYBA, ASAP1, MAP2K4, RNASE2, NIPSNAP2, MMP1, EWSR1, CCL28, LEG1, ACBP, APOM, TFF3, FOLR1, WFDC2, SERPINA1, SLURP1, DEFB4A, SLPI, IGFBP7, IGLV1-51, SERPINI1, IGLV3-9, SERPINA3, SPATS2L, APOC1, IGKV2-29, and KALRN.SELECTED DRAWING: Figure 1

The invention discloses a drug delivery system taking tumor vascular endothelial cells as targets and application of the drug delivery system, and belongs to the technical field of biological medicines. The invention provides a delivery carrier taking a tumor vascular endothelial cell as a target spot. The delivery carrier comprises an exosome and MMRN2 and / or IGFBP7 protein modified at an extracellular domain of an exosome membrane protein. The invention further provides a drug delivery system with tumor vascular endothelial cells as targets, and the drug delivery system comprises the delivery carrier and tumor treatment drugs wrapped in the delivery carrier. The exosome is modified to target CD93 molecules on the surface of glioma vascular endothelial cells, so that the drug is enriched in glioma, the curative effect is enhanced, and the safety is improved; the compound can specifically activate inflammation signal channels in glioma vascular endothelial cells, induce inflammatory response in glioma and remodel tumor-associated macrophages, can directly inhibit tumor growth, can promote presentation of tumor-associated antigens, and induces strong tumor specific immune response.

The invention provides application of secreted protein insulin-like growth factor binding protein 7 (IGFBP7) in diabetic foot ulcer attack risk prediction of diabetic patients, and belongs to the technical field of biological medicine. Through single cell sequencing, the secretory protein IGFBP7 is found to be highly expressed in smooth muscle cells of the diabetic foot ulcer disease site of a diabetic patient, so that the secretory protein IGFBP7 can be used as a marker for predicting the diabetic foot ulcer disease risk of the diabetic patient. The invention provides a new method for predicting the attack risk of diabetic foot ulcer of diabetic patients, and has important clinical value.

The invention belongs to the technical field of medical biology, and particularly relates to application of IGFBP7 in preparation of a medicine for treating gastric adenocarcinoma. IGFBP7 closely related to gastric adenocarcinoma is screened out as a molecular marker through multiple bioinformatics technologies, expression of IGFBP7 in gastric adenocarcinoma is detected through immunohistochemistry, and prognosis of a patient is evaluated by establishing a scoring system combining dyeing intensity and positive cell proportion. Experimental results show that IGFBP7 knock-down can effectively inhibit proliferation and migration of gastric adenocarcinoma cells, induce apoptosis and trigger S-phase arrest. Furthermore, a co-culture experiment of gastric adenocarcinoma cells and mononuclear cells reveals that IGFBP7 can promote polarization of M2 type macrophages in a gastric adenocarcinoma tumor immune microenvironment.

The present invention relates to a method for differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) in a subject suffering from heart failure, said method comprising the steps of determining the amounts of IGFBP7 (Insulin-like growth factor-binding protein 7), of a BNP-type peptide, and optionally of CRP (C-reactive protein) in a sample from the subject, calculating (i) a ratio of the amount of IGFBP7 and the amount of the BNP-peptide or (ii) a ratio of the sum of the amounts of IGFBP7 and CRP and the amount of the BNP-type peptide, comparing the ratio calculated with a reference ratio, and differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The present invention further concerns a method for the diagnosis of HFpEF.

The invention belongs to the field of cell biology, and particularly relates to a volmetinib-resistant non-small cell lung cancer cell strain HCC827 / FR and application thereof. The preservation number of the non-small cell lung cancer cell strain HCC827 / FR resistant to the vomitinib is CCTCC (China Center For Type Culture Collection) NO: C202583; the 19 exon of the volmetinib-resistant non-small cell lung cancer cell strain HCC827 / FR is subjected to deletion mutation; the drug-resistant gene of the non-small cell lung cancer cell strain HCC827 / FR resistant to the vomitinib is IGFBP7 (insulin-like growth factor binding protein 7). The vomitinib-resistant non-small cell lung cancer cell strain HCC827 / FR provided by the invention can be used for researching a vomitinib drug-resistant mechanism, constructing an in-vivo and in-vitro drug-resistant tumor model, screening an anti-tumor drug, evaluating drug sensitivity, developing a drug-resistant reversal drug based on an IGFBP7 gene, and researching a phenotype transformation mechanism from non-small cell lung cancer to small cell lung cancer after EGFR-TKI treatment.

The invention belongs to the technical field of genetic breeding, and particularly relates to application of a DNA fragment to regulation and control of IGFBP7 gene expression quantity and bovine fat deposition capacity, the DNA fragment refers to PAV16, and the base sequence of the PAV16 is shown as SEQ ID NO.1. The invention also relates to application of the DNA fragment to regulation and control of IGFBP7 gene expression quantity and bovine fat deposition capacity. The method comprises the following steps: identifying a large-fragment SV variation sequence in a first intron region of IGFBP7, namely PAV16; the invention further proves that the SV has enhancer activity and can influence the gene expression of IGFBP7 in bovine precursor fat cell subtypes to regulate and control fat deposition, and the SV variation sequence can be used as an important target in beef cattle breeding and provides necessary materials for breeding beef cattle groups with high economic benefits.

The present invention relates to a method for distinguishing between ejection fraction retention type heart failure (HFpEF) and ejection fraction reduction type heart failure (HFrEF) in a subject suffering from heart failure, the method comprising the steps of determining the amounts of IGFBP7 (Insulin-like Growth Factor Binding Protein 7), BNP-type peptide and optionally CRP (C-Reactive Protein) in a sample from the subject, the present invention relates to a method for distinguishing ejection fraction retention type heart failure (HFpEF) from ejection fraction reduction type heart failure (HFrEF) by using a BNP peptide, calculating (i) a ratio of the amount of the IGFBP7 to the amount of the BNP peptide or (ii) a ratio of a sum of the amounts of the IGFBP7 and the CRP to the amount of the BNP type peptide, comparing the calculated ratio with a reference ratio, and distinguishing ejection fraction retention type heart failure (HFpEF) from ejection fraction reduction type heart failure (HFrEF). The invention also relates to a method for diagnosing HFpEF.

The application discloses application of anti-IGFBP7 antibodies in treating skin diseases, belongs to the technical field of psoriasis treatment, and discloses application of anti-IGFBP7 antibodies in preparation of a medicament for treating psoriasis, wherein the medicament is used for reducing and treating psoriasis-like inflammation by inhibiting expression of IGFBP7 in blood vessels of skin of a psoriasis patient. After the anti-IGFBP7 antibodies are used, psoriasis inflammation is reduced, meanwhile, epidermal thickness of a psoriasis patient is reduced, erythema formation is inhibited, and the generation of scales is reduced. In protecting vascular barrier function and treating psoriasis, the anti-IGFBP7 antibodies have a good medicinal prospect.

The invention discloses a biomarker for pulmonary arterial hypertension right ventricular failure and application of the biomarker, layering of pulmonary arterial hypertension right ventricular failure is determined by detecting the content of IGFBP7 in a plasma sample, and early diagnosis is carried out; a small molecule drug targeting IGFBP7 is designed, binding of the small molecule drug with a receptor or a downstream signal channel is competitively inhibited, endothelial-to-mesenchymal transition (EndMT) is blocked, or a specific monoclonal antibody and an active site targeting IGFBP7 are developed, and pulmonary arterial hypertension right ventricular failure is relieved. By detecting the IGFBP7 level, the high pressure diagnosis accuracy of the pulmonary arterial hypertension and the right ventricular failure is improved, and accurate layering of the right ventricular failure is achieved. The application value of the IGFBP7 in PAH management is verified through the strong correlation between the IGFBP7 level and RHC parameters (mPAP, PVR and NT-proBNP) and the negative correlation between the IGFBP7 level and the heart function (heart index and stroke output), and a new direction is provided for treatment of right ventricular failure by preparing an IGFBP7 inhibitor and an antibody.

The present invention relates to a method for differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) in a subject suffering from heart failure, said method comprising the steps of determining the amounts of IGFBP7 (Insulin-like growth factor-binding protein 7), of a BNP-type peptide, and optionally of CRP (C-reactive protein) in a sample from the subject, calculating (i) a ratio of the amount of IGFBP7 and the amount of the BNP-peptide or (ii) a ratio of the sum of the amounts of IGFBP7 and CRP and the amount of the BNP-type peptide, comparing the ratio calculated with a reference ratio, and differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The present invention further concerns a method for the diagnosis of HFpEF.